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Mifepristone Pretreatment for the Medical Management of Early
Pregnancy Loss
Abstract

BACKGROUND
Medical management of early pregnancy loss is an alternative to uterine aspira-tion, but standard medical
treatment with misoprostol commonly results in treat-ment failure. We compared the efficacy and safety of
pretreatment with mifepris-tone followed by treatment with misoprostol with the efficacy and safety of
misoprostol use alone for the management of early pregnancy loss.
METHODS
We randomly assigned 300 women who had an anembryonic gestation or in whom embryonic or fetal death
was confirmed to receive pretreatment with 200 mg of mifepristone, administered orally, followed by 800 µg
of misoprostol, adminis-tered vaginally (mifepristone-pretreatment group), or 800 µg of misoprostol alone,
administered vaginally (misoprostol-alone group). Participants returned 1 to 4 days after misoprostol use for
evaluation, including ultrasound examination, by an in-vestigator who was unaware of the treatment-group
assignments. Women in whom the gestational sac was not expelled were offered expectant management, a
second dose of misoprostol, or uterine aspiration. We followed all participants for 30 days after
randomization. Our primary outcome was gestational sac expulsion with one dose of misoprostol by the first
follow-up visit and no additional intervention within 30 days after treatment.
RESULTS
Complete expulsion after one dose of misoprostol occurred in 124 of 148 women (83.8%; 95% confidence
interval [CI], 76.8 to 89.3) in the mifepristone-pretreat-ment group and in 100 of 149 women (67.1%; 95%
CI, 59.0 to 74.6) in the miso-prostol-alone group (relative risk, 1.25; 95% CI, 1.09 to 1.43). Uterine aspiration
was performed less frequently in the mifepristone-pretreatment group than in the misoprostol-alone group
(8.8% vs. 23.5%; relative risk, 0.37; 95% CI, 0.21 to 0.68). Bleeding that resulted in blood transfusion
occurred in 2.0% of the women in the mifepristone-pretreatment group and in 0.7% of the women in the
misoprostol-alone group (P = 0.31); pelvic infection was diagnosed in 1.3% of the women in each group.
CONCLUSIONS
Pretreatment with mifepristone followed by treatment with misoprostol resulted in a higher likelihood of
successful management of first-trimester pregnancy loss than treatment with misoprostol alone. (Funded by
the National Institute of Child Health and Human Development; PreFaiR ClinicalTrials.gov number,
NCT02012491.)
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a bs t r ac t
BACKGROUND

Medical management of early pregnancy loss is an alternative to uterine aspiration, but standard medical treatment with misoprostol commonly results in treatment failure. We compared the efficacy and safety of pretreatment with mifepristone followed by treatment with misoprostol with the efficacy and safety of
misoprostol use alone for the management of early pregnancy loss.
METHODS

We randomly assigned 300 women who had an anembryonic gestation or in whom
embryonic or fetal death was confirmed to receive pretreatment with 200 mg of
mifepristone, administered orally, followed by 800 μg of misoprostol, administered vaginally (mifepristone-pretreatment group), or 800 μg of misoprostol alone,
administered vaginally (misoprostol-alone group). Participants returned 1 to 4 days
after misoprostol use for evaluation, including ultrasound examination, by an investigator who was unaware of the treatment-group assignments. Women in whom
the gestational sac was not expelled were offered expectant management, a second
dose of misoprostol, or uterine aspiration. We followed all participants for 30 days
after randomization. Our primary outcome was gestational sac expulsion with one
dose of misoprostol by the first follow-up visit and no additional intervention
within 30 days after treatment.
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RESULTS

Complete expulsion after one dose of misoprostol occurred in 124 of 148 women
(83.8%; 95% confidence interval [CI], 76.8 to 89.3) in the mifepristone-pretreatment group and in 100 of 149 women (67.1%; 95% CI, 59.0 to 74.6) in the misoprostol-alone group (relative risk, 1.25; 95% CI, 1.09 to 1.43). Uterine aspiration
was performed less frequently in the mifepristone-pretreatment group than in the
misoprostol-alone group (8.8% vs. 23.5%; relative risk, 0.37; 95% CI, 0.21 to 0.68).
Bleeding that resulted in blood transfusion occurred in 2.0% of the women in the
mifepristone-pretreatment group and in 0.7% of the women in the misoprostolalone group (P = 0.31); pelvic infection was diagnosed in 1.3% of the women in
each group.
CONCLUSIONS

Pretreatment with mifepristone followed by treatment with misoprostol resulted
in a higher likelihood of successful management of first-trimester pregnancy loss
than treatment with misoprostol alone. (Funded by the National Institute of Child
Health and Human Development; PreFaiR ClinicalTrials.gov number, NCT02012491.)
n engl j med 378;23
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irst-trimester miscarriage, or early
pregnancy loss, is the most common complication in pregnancy and affects approximately 1 million women in the United States
annually.1,2 Subtypes of early pregnancy loss include anembryonic gestation and embryonic or
fetal death, inevitable abortion, and incomplete
abortion.3,4 Before the advent of home pregnancy
testing and early ultrasonography, women often
presented with heavy bleeding or signs of infection requiring prompt treatment with dilation
and curettage.5 Currently, women frequently receive a diagnosis of early pregnancy loss before
the onset of symptoms. This decrease in exigent
presentations has led to an interest in pursuing
nonsurgical treatment options for pregnancy
loss.6,7 Although some women pursue expectant
management, women generally prefer active
management6,8-12; the ability to have control over
the management of miscarriage may relieve some
of the emotional burden that accompanies firsttrimester pregnancy loss.12-14
Medical management of early pregnancy loss
with prostaglandin analogues allows for planned,
expedited expulsion of the nonviable pregnancy
tissue, with the goal of avoiding a surgical procedure. Misoprostol is stable at room temperature and can be administered by the woman
herself, which allows the tissue expulsion to
occur in the privacy of a woman’s home at a time
she chooses.15 Medical management is highly
desired by many women, and the use of misoprostol is recommended by society guidelines in
the United States and throughout the world.16,17
Unfortunately, the standard dose of 800 μg of
misoprostol, administered vaginally, has low efficacy among women with a closed cervical os.
As many as 15 to 40% of such women require a
second dose of misoprostol, which prolongs the
treatment period, or ultimately require the uterine
evacuation procedure they wished to avoid.3,7-9,18
The rate of failure diminishes the clinical usefulness of this strategy in practice.12
Mifepristone is a 19-nor steroid that acts as a
competitive progesterone-receptor antagonist and
a glucocorticoid-receptor antagonist and primes
the myometrium and cervix for prostaglandin
activity.15,19,20 The reported effectiveness of combination treatment with mifepristone and misoprostol for early pregnancy loss has ranged from
52 to 95%.3,10,11,21,22 This wide range is due in part
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to heterogeneity in study designs and outcome
definitions.3 To date, the usefulness of mifepristone in the treatment of early pregnancy loss has
remained unclear. We performed a randomized
trial to compare the efficacy and safety of pretreatment with mifepristone followed by treatment with misoprostol with misoprostol use
alone for the management of anembryonic gestation and embryonic or fetal death in women in
clinically stable condition who have a closed
cervical os.

Me thods
Trial Design

From May 2014 through April 2017, women who
received a diagnosis of anembryonic gestation or
embryonic or fetal death were referred to the
study team for screening; an investigator confirmed eligibility before enrollment. All participants provided written informed consent. The
Comparative Effectiveness of Pregnancy Failure
Management Regimens (PreFaiR) trial was approved by the institutional review boards at the
University of Pennsylvania, the University of California, Davis, and the Albert Einstein College of
Medicine. All the authors vouch for the completeness and accuracy of the data and analyses
and for the fidelity of the trial to the protocol.
Mifepristone (Mifeprex) was purchased from the
manufacturer (Danco Laboratories) at a research
price for use in the trial and was dispensed at
the trial sites; the manufacturer had no other
role in the trial. The protocol, including the statistical analysis plan, is available with the full
text of this article at NEJM.org.
Participants

Healthy women 18 years of age or older were
eligible if they had an ultrasound examination
that showed a nonviable intrauterine pregnancy
between 5 and 12 completed weeks of gestation.
We excluded women who had an incomplete or
inevitable abortion (defined as the absence of a
gestational sac, an open cervical os, or both)
because of the high efficacy of misoprostol use
alone in women with these diagnoses.4 Women
were also excluded if they had a contraindication
to mifepristone or misoprostol, had any evidence
of a viable or ectopic pregnancy, had a hemoglobin level lower than 9.5 g per deciliter, had a
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randomization to collect information about additional treatments or adverse events. At this
time, participants assessed bleeding and pain
(on Likert scales, on which scores ranged from
1 to 5, with lower scores indicating greater bleedTrial Procedures
ing and pain) and responded to standard quesWe randomly assigned the participants to receive tions regarding the acceptability of treatment.8,24,25
pretreatment with 200 mg of mifepristone, administered orally, followed by 800 μg of miso- Outcomes and Adverse Events
prostol, administered vaginally approximately 24 The primary outcome was gestational sac expulhours later (mifepristone-pretreatment group), sion by the first follow-up visit with one dose of
or standard therapy with 800 μg of misoprostol misoprostol and no additional surgical or medialone, administered vaginally (misoprostol-alone cal intervention within 30 days after treatment;
group), on trial day 1. Participants were randomly the attainment of the primary outcome was clasassigned in permuted blocks of two to eight, sified as treatment success. We chose this pristratified according to trial site, with the use of mary outcome in accordance with patient preferResearch Electronic Data Capture software ences for the treatment to work promptly and
(REDCap, Vanderbilt University). Women who effectively. We also planned assessments of the
were assigned to the mifepristone-pretreatment treatment outcomes at the day 8 and day 30 time
group swallowed the mifepristone in front of points according to three commonly used clinione of the trial staff members. In accordance cal metrics: the rate of gestational sac expulsion
with our pragmatic trial design, the women in with one dose of misoprostol, the rate of gestathe misoprostol-alone group did not receive pla- tional sac expulsion with two doses of misoprocebo.23 We instructed all participants in both stol, and the percentage of women who undertreatment groups to insert four misoprostol tab- went uterine aspiration. Additional prespecified
lets (200 μg per tablet) vaginally at home approxi- secondary outcomes (for which results are premately 24 hours after randomization. We offered sented in the current report) included adverse
women oral analgesics according to the local effects (including bleeding and pain, as measured
standards at each trial site. Trial staff provided on Likert scales), acceptability of treatment (an
each participant a diary to record information overall assessment of the treatment, as measured
about bleeding, symptoms, and pain medication on a 3-point scale [with “good” indicating a
use. Participants were scheduled for an initial positive experience, “bad” a negative experience,
follow-up appointment at least 24 hours (but not or neutral] and with the question, “Would you
more than 4 days) after misoprostol use (trial recommend this method of treatment to a
friend?”), and assessment of clinical characterisday 3).
At the initial follow-up visit, an investigator tics associated with complete gestational sac
who was unaware of the treatment-group assign- expulsion; assessments of quality of life, costs,
ments assessed the outcome by means of endo- and biomarkers that predict complete gestational
vaginal ultrasonography. If the gestational sac sac expulsion were performed, but the data are
was absent, a follow-up telephone call was not presented here.
scheduled approximately 1 week after randomization. If the gestational sac was present, we Statistical Analysis
offered women a second dose of misoprostol or On the basis of previous research, we expected
expectant or surgical management. Participants the rate of treatment success with a single dose
who chose expectant management or a second of misoprostol to be 80 to 90% in the mifeprisdose of misoprostol returned for an additional tone-pretreatment group and 60 to 71% in the
follow-up visit approximately 8 days (range, 6 to misoprostol-alone group.8,10,18 We estimated that
12) after randomization for evaluation by an a sample size of 134 participants per treatment
investigator who was unaware of the treatment- group would provide adequate power to detect a
group assignments. We contacted all participants 15 percentage-point difference in the rate of
by telephone 30 days (range, 25 to 36) after treatment success (85% in the mifepristoneknown clotting defect or were receiving anticoagulants, had a pregnancy with an intrauterine
device in place, or were unwilling to adhere to
the trial protocol.
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800 Participants were assessed
for eligibility

497 Were excluded
79 Did not meet inclusion
criteria
108 Declined to participate
300 Were not interested
in medical management
10 Had other reason
303 Consented to participate
in the study
3 Did not meet screening criteria
for inclusion

300 Underwent randomization

149 Were assigned to the mifepristonepretreatment group

151 Were assigned to the misoprostolalone group

148 Were included in the initial follow-up
1 Discontinued because of clinical
ineligibility

149 Were included in the initial follow-up
1 Was lost to follow-up
1 Withdrew consent

141 Were included in 8-day and 30-day
follow-up
7 Were lost to follow-up

142 Were included in 8-day and 30-day
follow-up
6 Were lost to follow-up
1 Withdrew consent

149 Were included in the baseline data
analysis
148 Were included in the primary
outcome analysis
141 Were included in the 30-day
follow-up analysis

151 Were included in the baseline data
analysis
149 Were included in the primary
outcome analysis
142 Were included in the 30-day
follow-up analysis

Figure 1. Enrollment, Randomization, Follow-up, and Analysis.
Participants assigned to the mifepristone-pretreatment group received 200 mg
of mifepristone, administered orally, followed by 800 μg of misoprostol, administered vaginally approximately 24 hours later, and those assigned to the
misoprostol-alone group received 800 μg of misoprostol alone, administered
vaginally. All participants received the assigned treatment.
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cruitment goal of 300 women. Data analysis
were performed with Stata software, version 15
(StataCorp). Standard descriptive methods were
used to summarize the trial population overall
and by treatment group. The primary outcome
was assessed among all women who had at least
one follow-up visit according to a preplanned
modified intention-to-treat principle. After testing for homogeneity of the primary outcome
among trial sites, we calculated the percentage
(with 95% confidence interval) of women in each
treatment group who had treatment success and
compared the results using two-sided Mantel–
Haenszel combined relative risks at an alpha
level of 0.047 (an alpha level of 0.003 was allocated to the interim analysis). We computed the
effect of loss to follow-up by performing a sensitivity analysis in which the outcome that was
most in favor of no treatment effect (i.e., failure
in the mifepristone-pretreatment group and success in the misoprostol-alone group) was assigned
to each participant who was lost to follow-up.
Subgroup analyses of the primary outcome
according to patient demographics and clinical
characteristics were prespecified; we performed
analyses that were stratified according to gestational age, parity, gravidity, and diagnosis (embryonic or fetal death vs. anembryonic gestation). (The protocol also specified an analysis
according to presenting symptoms, but this was
not performed owing to the low percentage of
participants who presented with bleeding.) Twosided Mantel–Haenszel combined relative risks
were used to compare treatment groups in all
secondary analyses; the results are presented
without adjustment for multiplicity and should
be considered exploratory. In accordance with
the protocol, the data and safety monitoring
committee performed one interim analysis for
safety and futility after recruitment of half the
participants; on the basis of the findings from
this interim analysis, the trial was continued.

R e sult s
Participants

pretreatment group vs. 70% in the misoprostolalone group). Allowing for a single interim
analysis under a group sequential design and a
loss to follow-up of 5%, we set an overall re-
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From May 2014 through April 2017, we assessed
800 women for eligibility; 497 women were excluded and 303 consented to participate (Fig. 1).
The most common reason for declining participation was a preference for uterine aspiration
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over medical management. Of the 303 women
enrolled, 3 did not meet screening criteria for
inclusion; thus, 300 women underwent randomization, with 149 assigned to the mifepristonepretreatment group and 151 assigned to the
misoprostol-alone group. All the participants
completed the trial according to the protocol
with the exception of 2 women who were lost to
follow-up and 1 woman who was determined
to be clinically ineligible after randomization
because of suspicion of a cesarean-section-scar
ectopic pregnancy (an ectopic pregnancy implanted in scar tissue from a previous cesarean
section). Baseline characteristics were similar in
the two treatment groups (Table 1).
Outcomes

Initial Follow-up

The median number of days between the time of
misoprostol administration and the first followup visit was 2.0 (range, 0.5 to 5.5) in the mifepristone-pretreatment group and 2.6 (range, 0.7
to 9.6) in the misoprostol-alone group (P = 0.04).
Treatment success by the first follow-up visit,
with no additional interventions needed within
30 days after treatment, occurred in 124 of 148
women (83.8%; 95% confidence interval [CI],
76.8 to 89.3) in the mifepristone-pretreatment
group and in 100 of 149 women (67.1%; 95% CI,
59.0 to 74.6) in the misoprostol-alone group
(absolute difference in the rate of treatment success, 16.7 percentage points [95% CI, 7.1 to
26.3]; relative risk of expulsion with one dose of
misoprostol, 1.25 [95% CI, 1.09 to 1.43]) (Table 2). The results were similar in a sensitivity
analysis that assumed that the outcomes in the
women who were lost to follow-up were most in
favor of no treatment effect (i.e., treatment failure with mifepristone pretreatment and treatment success with misoprostol alone) (relative
risk, 1.21; 95% CI, 1.05 to 1.38). In the mifepristone-pretreatment group, 65 women (43.6%) did
not wait the full 24 hours before administering
misoprostol (mean [±SD] number of hours waited, 12.0±7.3), of whom 45 (69.2%) waited for less
than 18 hours. The rate of treatment success
among women who not wait the full 24 hours
before administering misoprostol was 79.7%, as
compared with 86.9% among the women who
waited for 24 hours (P = 0.24). The number
needed to pretreat with mifepristone to attain an

n engl j med 378;23

additional outcome of treatment success by the
first follow-up visit was 6.
Day 8 Follow-up

Gestational sac expulsion did not occur by the
first follow-up visit in 24 women in the mifepristone-pretreatment group (16.2%) and in 49
women in the misoprostol-alone group (32.9%);
among these women, 41% chose expectant management, 27% chose a second dose of misoprostol, and 31% underwent uterine aspiration (Table S1 in the Supplementary Appendix, available
at NEJM.org). Among the women who did not
have treatment success by the first follow-up
visit, there were no significant between-group
differences in the proportion of women who
chose each additional intervention (P = 0.12).
Complete expulsion of the gestational sac with
one dose of misoprostol by day 8 occurred in
130 of 148 women (87.8%; 95% CI, 81.5 to 92.6)
in mifepristone-pretreatment group and in 106
of 149 women (71.1%; 95% CI, 63.2 to 78.3) in
the misoprostol-alone group (relative risk, 1.23;
95% CI, 1.10 to 1.39).
Day 30 Follow-up

One month after randomization, the cumulative
rate of gestational sac expulsion with up to two
doses of misoprostol was 91.2% (95% CI, 85.4
to 95.2) in the mifepristone-pretreatment group
and 75.8% (95% CI, 68.2 to 82.5) in the misoprostol-alone group. By the end of the trial period
at day 30, a total of 13 women (8.8%; 95% CI,
4.8 to 14.6) in the mifepristone-pretreatment
group and 35 women (23.5%; 95% CI, 16.9 to
31.1) in the misoprostol-alone group had undergone uterine aspiration (absolute difference, 14.7
percentage points [95% CI, 6.5 to 22.9]; relative
risk, 0.37 [95% CI, 0.21 to 0.68]) (Table 2).
We performed subgroup analyses stratified according to length of gestation, parity, gravidity,
and diagnosis (embryonic or fetal death vs. anembryonic gestation). Rates of treatment success by
the first follow-up visit among women who were
at 9 weeks of gestation or less were 84.8% (117 of
138 women) in the mifepristone-pretreatment
group and 66.7% (94 of 141 women) in the
misoprostol-alone group. No significant betweengroup differences were found in the effect of the
intervention according to subgroups stratified by
gestation, gravidity, parity, or diagnosis (Fig. 2).
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Table 1. Characteristics of the Participants at Baseline.*
Mifepristone-Pretreatment
Group
(N = 149)

Misoprostol-Alone
Group
(N = 151)

30.7±6.3

30.2±6.0

Black

65 (43.6)

67 (44.4)

White

57 (38.3)

52 (34.4)

Hispanic

38 (25.5)

38 (25.5)

Characteristic
Age — yr
Race or ethnic group — no. (%)†

Asian

9 (6.0)

11 (7.3)

Other

18 (12.1)

21 (13.9)

Education‡
Some grade school or high school

10 (6.8)

17 (11.3)

High-school diploma or GED

46 (31.1)

56 (37.1)

Some college or post–high-school education

92 (62.2)

78 (51.7)

Medical insurance‡
None

13 (8.8)

11 (7.3)

Medicaid or Medicare

64 (43.2)

78 (51.7)

Private insurance

71 (48.0)

62 (41.1)

1

37 (24.8)

32 (21.2)

2

36 (24.2)

27 (17.9)

≥3

76 (51.0)

92 (60.9)

0

63 (42.3)

52 (34.4)

≥1

86 (57.7)

99 (65.6)

Living children

87 (58.4)

94 (62.3)

Previous miscarriage

53 (35.6)

52 (34.4)

4–5 wk

15 (10.1)

10 (6.6)

6 wk

44 (29.5)

38 (25.2)

7 wk

34 (22.8)

46 (30.5)

8 wk

31 (20.8)

34 (22.5)

9 wk

14 (9.4)

15 (9.9)

10–12 wk

11 (7.4)

8 (5.3)

Gravidity

Parity

Gestation

Diagnosis
Anembryonic gestation

40 (26.8)

37 (24.5)

Embryonic or fetal death

109 (73.2)

114 (75.5)

Yes

18 (12.1)

17 (11.3)

No

111 (74.5)

119 (78.8)

20 (13.4)

15 (9.9)

Any bleeding before randomization

Unknown

*	Plus–minus values are means ±SD. Participants assigned to the mifepristone-pretreatment group received 200 mg of
mifepristone, administered orally, followed by 800 μg of misoprostol, administered vaginally approximately 24 hours
later, and those assigned to the misoprostol-alone group received 800 μg of misoprostol alone, administered vaginally.
There were no significant differences between the groups in any of the characteristics listed. Percentages may not sum
to 100 because of rounding.
†	Race and ethnic group were reported by the participants.
‡	One participant in the mifepristone-pretreatment group was excluded because of missing values.
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Table 2. Clinical Outcomes among Women Who Received Medical Treatment for Early Pregnancy Loss.
Mifepristone-Pretreatment
Group
(N = 148)

Outcome

Misoprostol-Alone
Group
(N = 149)

Relative Risk
(95% CI)*

number (percent)
Gestational sac expulsion by the first follow-up
visit: treatment success†

124 (83.8)

100 (67.1)

1.25 (1.09–1.43)‡

Gestational sac expulsion by the second followup visit at day 8

132 (89.2)

111 (74.5)

1.20 (1.07–1.33)

130 (87.8)

106 (71.1)

With 1 dose of misoprostol
With 2 doses of misoprostol

2 (1.4)

5 (3.4)

135 (91.2)

113 (75.8)

With 1 dose of misoprostol

130 (87.8)

106 (71.1)

With 2 doses of misoprostol

5 (3.4)

7 (4.7)

13 (8.8)

35 (23.5)

Gestational sac expulsion by the 30-day telephone call

Uterine aspiration§

1.20 (1.08–1.33)

0.37 (0.21–0.68)

*	Relative risks were adjusted for trial site with use of the Mantel–Haenszel method.
†	Treatment success was defined as gestational sac expulsion with one misoprostol dose by the first follow-up visit and
no additional intervention within 30 days after treatment.
‡	The rate of treatment success by the first follow-up visit was significantly higher in the mifepristone-pretreatment group
than in misoprostol-alone group (P<0.001).
§	Indications for uterine aspiration included participant request and clinical recommendation.

Side Effects and Acceptability of Treatment

The rates of serious adverse events and adverse
events by type are provided in Table 3. There
were no significant between-group differences
in the mean scores for bleeding intensity (1.8 in
both groups) or pain (2.7 in both groups). By the
end of the trial period, 89.4% of the women in
the mifepristone-pretreatment group and 87.4%
in the misoprostol-alone group described their
experience overall as either “good” or “neutral”;
the corresponding percentages of women who
stated that they would recommend their treatment
method to a friend were 87.0% and 89.6%. The
majority of women in each group (69.1% in
the mifepristone-pretreatment group and 64.8%
the misoprostol-alone group) also stated that they
would use medical management if they had another pregnancy loss.

Discussion
In this randomized trial involving women with
anembryonic gestation or in whom embryonic or
fetal death was confirmed, pretreatment with
mifepristone followed by treatment with misoprostol resulted in a significantly higher rate of
complete gestational sac expulsion by approximately 2 days after treatment than misoprostol
n engl j med 378;23

use alone. Pretreatment with mifepristone also
resulted in a significantly lower rate of uterine
aspiration than misoprostol use alone.
Even in the context of our pragmatic trial
design in which women received routine clinical
care after the first follow-up visit, we had high
rates of participant retention and adherence to
the protocol. Our trial population was diverse
with respect to sociodemographic status and
pregnancy diagnosis, which supports the generalizability of the results. We did not include a
placebo group in this pragmatic trial. Because
the primary outcome was not reported by the
participants but was assessed by an investigator
who was unaware of the treatment-group assignments, we do not expect that the lack of a placebo
group introduced bias related to the primary
outcome. It is possible that secondary efficacy
outcomes could have been affected, because
women in the misoprostol-alone group who did
not have gestational sac expulsion by the first
follow-up visit might have been less willing to
wait (i.e., to choose expectant management) until day 8 for tissue expulsion than those in the
mifepristone-pretreatment group, but we did not
find that the proportion of additional interventions differed significantly between the treatment
groups. We allowed for a short range of days at
nejm.org
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No. of Participants (%)

m e dic i n e

of

Relative Risk (95% CI)

Rate of Treatment Success

P Value

MifepristoneMisoprostolpretreatment group alone group
%
Overall
Diagnosis
Embryonic or fetal death
Anembryonic gestation
Gravidity
1
≥2
Parity
0
≥1
Gestation
4–5 wk
6 wk
7 wk
8 wk
9 wk
10–12 wk

297 (100)

83.8

67.1

220 (74)
77 (26)

85.2
80.0

67.9
64.9

69 (23)
228 (77)

86.5
82.9

78.1
64.1

114 (38)
183 (62)

85.7
82.4

70.6
65.3

25 (8)
82 (28)
80 (27)
64 (22)
28 (9)
18 (6)

93.3
81.8
84.8
87.1
85.7
70.0

60.0
63.2
69.6
72.7
57.1
75.0

0.81

0.56

0.97

0.72

0.5

1.0

Misoprostol Alone
Better

1.5

2.0

2.5

3.0

Mifepristone Pretreatment Better

Figure 2. Clinical Outcomes among Women Who Received Medical Treatment for Early Pregnancy Loss, Stratified According to Clinical
Characteristics.
Treatment success was defined as gestational sac expulsion with one dose of misoprostol by the first follow-up visit and no additional
intervention within 30 days after treatment. P values were calculated from tests of interaction between the treatment groups and the
subgroup variables.

which we initially assessed the primary outcome
to accommodate the scheduling preferences of the
participants. The slightly longer mean elapsed
time between misoprostol use and follow-up assessment in the misoprostol-alone group would
have biased against the benefit of pretreatment,
even though a significant benefit of pretreatment was found.
We evaluated the 800-μg dose of misoprostol,
administered vaginally, because this dose and
route of administration were best supported by
the literature at the time of the development of
our protocol.3,10,26 Misoprostol can also be administered orally, rectally, buccally, or sublingually.
Administration through the buccal route results
in uterine tone and activity that are similar to
those with the vaginal route,27 and the sublingual route results in more rapid absorption and
higher peak levels than the vaginal route.28 When
misoprostol is used to induce a first-trimester
abortion, vaginal administration is more effective than oral administration and may have
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fewer side effects than the sublingual or buccal
route.29 Vaginal administration also permits efficacy at an interval of less than 24 hours after
mifepristone administration among patients undergoing abortion.25,30,31 Many of our participants
chose not to wait the full 24 hours between
mifepristone pretreatment and misoprostol use;
future studies could test whether a shorter interval between the administration of these medications affects the efficacy of treatment for early
pregnancy loss.
In 2000, the Food and Drug Administration
first approved mifepristone for use with misoprostol to end an early pregnancy. This approval
included Risk Evaluation and Mitigation Strategy
requirements with the stated goal of mitigating
the risk of serious complications associated with
use of the drug. Although our study was not
powered to show differences between groups
in the proportions of serious adverse events,
such events were rare — a finding that is consistent with the results of other published stud-
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Table 3. Adverse Events among Women Who Received Medical Treatment for Early Pregnancy Loss.

Event

Mifepristone-Pretreatment
Group
(N = 149)

Misoprostol-Alone
Group
(N = 151)

Relative Risk or
Incidence Rate Ratio
(95% CI)*

P Value

Serious adverse events reported by participants
Total number (rate per 100 women†)

5 (3.4)

3 (2.0)

1.68 (0.40–7.05)

0.47

Bleeding resulting in blood transfusion
— no. of participants (%)

3 (2.0)

1 (0.7)

3.04 (0.32–28.6)

0.31

Pelvic infection — no. of participants (%)‡

2 (1.3)

2 (1.3)

1.01 (0.15–7.01)

0.99

Total no.

904

843

Mean no. per participant

6.1

5.6

1.09 (0.99–1.19)

0.08

118 (79.2)

115 (76.2)

1.04 (0.92–1.17)

0.53

88 (59.1)

72 (47.7)

1.24 (1.00–1.54)

0.05

Adverse events reported by participants

Type of event — no. of participants (%)
Fatigue
Headache
Dizziness or lightheadedness

78 (52.3)

68 (45.0)

1.16 (0.92–1.47)

0.20

Chills

68 (45.6)

70 (46.4)

0.99 (0.77–1.26)

0.90

Nausea

56 (37.6)

56 (37.1)

1.01 (0.76–1.36)

0.93

Diarrhea

41 (27.5)

44 (29.1)

0.94 (0.66–1.35)

0.76

Vomiting

40 (26.8)

23 (15.2)

1.76 (1.11–2.79)

0.01

Severe cramping

20 (13.4)

21 (13.9)

0.97 (0.58–1.61)

0.90

Fever

10 (6.7)

9 (6.0)

1.12 (0.47–2.68)

0.79

*	The rates for the total number of serious adverse events and mean number of adverse events were compared with the use of incidence rate
ratios, with adjustment for trial site. The percentages of women who had each type of adverse event were compared with the use of relative
risks that were adjusted for trial site with the Mantel–Haenszel method.
†	The rate per 100 women is shown to account for the fact that a woman could have more than one event.
‡	Pelvic infection includes diagnoses of endometritis and septic abortion.

ies.11,21,24,26,32 Studies of the use of mifepristone
for induced abortion or for the treatment of
early pregnancy loss have not shown a risk profile that supports such regulatory limitations on
prescription.33,34
In conclusion, this randomized trial showed
that pretreatment with mifepristone followed by
treatment with misoprostol resulted in a higher
likelihood of prompt and effective treatment of
early pregnancy loss than misoprostol use
alone.
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